Clinical trials: CtDNA
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
This phase II/III trial studies how well circulating tumor deoxyribonucleic acid (ctDNA) testing in the blood works in predicting treatment for patients with stage IIA colon cancer after surgery.
- Trial name
- NCT04068103
- Testing
- Capecitabine, Fluorouracil, Leucovorin
- Where
- 957 sites in United States, Canada and 1 more
- Volunteers
- 635 people
- Sponsor
- NRG Oncology
Hepatobiliary Cancer, Pancreatic Cancer
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies…
- Conditions
- Hepatobiliary Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT05497531
- Testing
- ctDNA Blood Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Irvine
Lung Neoplasms, EGFR Gene Mutations
Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from…
- Trial name
- LiquidLung-O (NCT02769286)
- Testing
- Osimertinib
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Chonnam National University Hospital
Pancreatic Cancer, Pancreatic Adenocarcinoma
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer
Pancreatic cancer (PC) is a deadly disease and surgical resection of the tumor is the only hope of cure. Approximately 20-25% of the PC patients are candidates for intended curative resection, but despite microscopically radical…
- Trial name
- LIPAC (NCT05400681)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Sonke Detlefsen
Breast Cancer, ER-positive Breast Cancer
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
The majority of patients (pts) with breast cancer have hormone receptor positive (HR+) disease, and this holds true for pts with advanced breast cancer (ABC).
- Conditions
- Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT05826964
- Testing
- AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Miami
Colorectal Cancer
Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients
The study aims to explore the clinical utility of circulating tumour DNA (ctDNA) in assessing for alterations of anti-epidermal growth factor receptor (EGFR) primary resistance in RAS and BRAF wild-type metastatic colorectal…
- Trial name
- NCT05051592
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National University Hospital, Singapore
ctDNA, Chemotherapy
Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer
This study will utilize ctDNA methylation detection to evaluate patients with high-risk T3N0 stage II colorectal cancer who are ctDNA-positive one month after surgery.
- Conditions
- ctDNA, Chemotherapy, Colorectal Cancer
- Trial name
- CLEAR-02 (NCT07562711)
- Testing
- Capecitabine, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Fudan University
Esophageal Cancer
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
This study was a multicenter, randomized, phase 3 trial to determine whether adjuvant chemotherapy including tisleliizumab improves recurrence-free survival compared to follow-up alone without chemotherapy in patients with…
- Trial name
- MRD2START (NCT06914011)
- Testing
- Tislelizumab
- Volunteers
- 172 people
- Sponsor
- Asan Medical Center
Colorectal Cancer
Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection
The DNA methylation targets in preoperative plasma samples of the subjects will be detected by the multi-gene methylation test (ColonAiQ), and the test accuracy will be evaluated by compared with the clinical diagnosis evidence.
- Trial name
- NCT06347887
- Testing
- ColonAiQ test and Colonoscopy
- Where
- 7 sites in China
- Volunteers
- 1,965 people, healthy volunteers welcome
- Sponsor
- Singlera Genomics Inc.
Non Small Cell Lung Cancer, Circulating Tumor Cell
WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC
Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, Circulating Tumor DNA
- Trial name
- WHENII (NCT03481101)
- Testing
- PET/CT
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM)
Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling
The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with…
- Conditions
- Colorectal Cancer (Diagnosis), Colorectal Liver Metastasis (CRLM), Circulating Tumor DNA (ctDNA)
- Trial name
- ctDNA TAP (NCT07310537)
- Testing
- Blood Collection - TAP® Device, Blood Collection - Venous
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
Glioma, Circulating Tumor Cell
Analysis of Circulating DNA in Blood Samples of Glioma-affected Patients
The present pilot study aims to investigate a new strategy in the liquid biopsy protocol for the diagnosis of gliomas based on the detection of circulating tumor DNA in the blood of patients with brain lesions compatible with…
- Trial name
- NCT05964153
- Testing
- Liquid Biopsy
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Corporacion Parc Tauli
Gastric Cancer Stage III
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
The goal of this randomized, controlled phase III clinical trial is to evaluate whether combining Tislelizumab with standard SOX chemotherapy improves disease-free survival (DFS) compared to chemotherapy alone in patients with…
- Trial name
- NCT06939439
- Testing
- Tislelizumab + SOX Chemotherapy, SOX Chemotherapy
- Where
- China
- Volunteers
- 416 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
NORPACT-3 is a nationwide, Norwegian single arm prospective study that evaluates the resectability rates and survival in patients with borderline resectable and locally advanced pancreatic cancer who received primary…
- Conditions
- Locally Advanced Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Pancreatectomy, Chemotherapy Effect
- Trial name
- NORPACT-3 (NCT06944587)
- Testing
- Chemotherapy, Radiology, Pancreatectomy
- Where
- 5 sites in Norway
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with…
- Trial name
- CURB-TKI (NCT06813664)
- Testing
- Radiotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Colon Cancer
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
PEGASUS is a prospective multi-centric study designed to prove the feasibility of using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon…
- Trial name
- NCT04259944
- Testing
- CAPOX, Capecitabine, FOLFIRI
- Where
- 11 sites in Italy, Spain
- Volunteers
- 140 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Hodgkin Lymphoma
Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients
Molecular analysis identifies residual disease by overcoming the sensitivity of imaging methods and therefore has the potential for integrating with therapy provided by FDG-PET alone.
- Trial name
- NCT05254821
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- Federico II University
Prostate Cancer Recurrent
Exploring the Mechanisms and Dynamics of Clonal Evolution Leading to Recurrence in Prostate Cancer
Prostate cancer is the most common cancer in males in the UK, and current estimates are that 1 in 8 will be diagnosed with prostate cancer in their lifetime.
- Trial name
- EXCERPT (NCT04686188)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Neoplasms
Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing.
- Trial name
- SCAN-B (NCT02306096)
- Where
- 10 sites in Sweden
- Volunteers
- 20,000 people
- Sponsor
- Lund University
Breast Cancer
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
This prospective study recruits patients with ER+/HER2-, non-metastatic breast cancer who omit upfront surgery in favor of primary endocrine therapy for sample collection and prospective circulating tumor DNA (ctDNA) measurement…
- Trial name
- NCT05914792
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Pittsburgh